BRIEF-Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications

Reuters

Feb 18

BRIEF-<a href="https://laohu8.com/S/TOVX">Theriva Biologics</a> Licenses Syn-020 To Rasayana <a href="https://laohu8.com/S/LENZ">Therapeutics</a> For Multiple Indications

Feb 18 (Reuters) - Theriva Biologics Inc TOVX.A:

THERIVA™ BIOLOGICS LICENSES SYN-020 TO RASAYANA THERAPEUTICS FOR MULTIPLE INDICATIONS
THERIVA BIOLOGICS INC: RECEIVED $300,000 UPFRONT PAYMENT AT SIGNING & ELIGIBLE FOR UP TO $38M IN MILESTONE PAYMENTS

Source text: ID:nGNE41C06S

Further company coverage: TOVX.A

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612449137"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612449137\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612449137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612449137","market":"fut","top_or_hot":-1,"title":"BRIEF-Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/TOVX\">Theriva Biologics</a> Licenses Syn-020 To Rasayana <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> For Multiple Indications</title></head><body><p><span>Feb 18 (Reuters)</span><span> - </span>Theriva Biologics Inc <span>TOVX.A</span>:</p><ul><li><p>THERIVA™ BIOLOGICS LICENSES SYN-020 TO RASAYANA THERAPEUTICS FOR MULTIPLE INDICATIONS</p></li><li><p>THERIVA BIOLOGICS INC: RECEIVED $300,000 UPFRONT PAYMENT AT SIGNING &amp; ELIGIBLE FOR UP TO $38M IN MILESTONE PAYMENTS</p></li></ul><p>Source text: <span>ID:nGNE41C06S</span></p><p>Further company coverage: <span>TOVX.A</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/TOVX\">Theriva Biologics</a> Licenses Syn-020 To Rasayana <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> For Multiple Indications</title></head><body><p><span>Feb 18 (Reuters)</span><span> - </span>Theriva Biologics Inc <span>TOVX.A</span>:</p><ul><li><p>THERIVA™ BIOLOGICS LICENSES SYN-020 TO RASAYANA THERAPEUTICS FOR MULTIPLE INDICATIONS</p></li><li><p>THERIVA BIOLOGICS INC: RECEIVED $300,000 UPFRONT PAYMENT AT SIGNING &amp; ELIGIBLE FOR UP TO $38M IN MILESTONE PAYMENTS</p></li></ul><p>Source text: <span>ID:nGNE41C06S</span></p><p>Further company coverage: <span>TOVX.A</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TOVX","symbol_name":"Theriva Biologics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nFWN3ZE02I:1","article_id":"2612449137","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612449137","pubTimestamp":1771423355,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple IndicationsFeb 18 (Reuters) - Theriva Biologics Inc TOVX.A:THERIVA BIOLOGICS LICENSES SYN-020 TO RASAYANA THERAPEUTICS FO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TOVX":"Theriva Biologics","BK4139":"生物科技"},"translate_title":"简介-Theriva Biologics将Syn-020授权给Rasayana Therapeutics用于多种适应症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TOVX":0.9},"content_text":"BRIEF-Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple IndicationsFeb 18 (Reuters) - Theriva Biologics Inc TOVX.A:THERIVA™ BIOLOGICS LICENSES SYN-020 TO RASAYANA THERAPEUTICS FOR MULTIPLE INDICATIONSTHERIVA BIOLOGICS INC: RECEIVED $300,000 UPFRONT PAYMENT AT SIGNING & ELIGIBLE FOR UP TO $38M IN MILESTONE PAYMENTSSource text: ID:nGNE41C06SFurther company coverage: TOVX.A ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}